Bleeding complications in secondary stroke prevention by antiplatelet therapy: A benefit-risk analysis

Journal of Internal Medicine

Volumn 246, Issue 3, 1999, Pages 239-245

  Boysen, Gudrun ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antiplatelet therapy; Aspirin; Benefit risk analysis; Haemorrhagic complications; Secondary stroke prevention; Stroke prevention trial

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE;

ACUTE HEART INFARCTION; BRAIN HEMORRHAGE; CONTROLLED STUDY; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; STROKE; TRANSIENT ISCHEMIC ATTACK;

ASPIRIN; CEREBROVASCULAR DISORDERS; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RISK; TICLOPIDINE; TREATMENT OUTCOME;

EID: 0032853392     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.00516.x     Document Type: Review

References (16)

1. Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989; 321: 129-35.
2. SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular events. Lancet 1991; 338: 1345-49.
3. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischaemic attack or minor ischaemic stroke. N Engl J Med 1991; 325: 1261-66.
4. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Löwenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
5. Gent M, Easton JD, Hachinski VC et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1; 1215-20.
6. Hass WK, Easton JD, Adams HP et al. For the Ticlopidine Aspirin Stroke Study Group. A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-507.
7. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
8. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-81.
9. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641-49.
10. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular events by prolonged antiplatelet therapy. Br Med J 1988; 296: 320-31.
11. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trial of antiplatelet therapy - I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 301: 81-106.
12. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiat 1996; 60: 197-99.
13. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br Med J 1988; 296: 316-20.
14. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmac 1993; 35: 219-26.
15. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 310: 827-30.
16. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413-16.